Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

BioCentury - Asif Ali to join Protagonist as CFO

Bio Tech Nutra Avenger - Stack3d Database

Avenge Bio CEO and Key Executive Team

Commercialization Highlights, Office of Technology Transfer, Office of Research

Enrollment information for DRUG FACTORY Implants in Ovarian Cancer Trial is now up on the Clinical Trials website! 👏 Check here:, By Ovarcome

Toxic Avenger, Superhero Wiki

MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk

Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Webinar on Clinical Manufacturing

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors